NurrOn Pharmaceuticals
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(781) 608-8144Website
www.nurronpharma.comRevenue
$9.4 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About NurrOn Pharmaceuticals
NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, USA, focused on developing innovative, disease-modifying therapies for Parkinson's disease and other Nurr1-related disorders. The company aims to enhance the quality of life for Parkinson's patients by creating targeted therapeutics that maximize efficacy while minimizing side effects. NurrOn's approach involves targeting Nurr1, a key regulator in dopaminergic neuron development, to slow or prevent disease progression. Their research includes both monotherapy and combination treatment strategies to improve clinical outcomes for patients.Explore more
Popular SearchesNurron Pharmaceuticals IncNurrOn PharmaceuticalsSIC Code 28,283NAICS Code 32,325Show moreNurrOn Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NurrOn Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if NurrOn Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if NurrOn Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at NurrOn Pharmaceuticals
Product Launch: Get notified when NurrOn Pharmaceuticals launches new products
Check if NurrOn Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
NurrOn Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NurrOn Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once NurrOn Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined NurrOn Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to NurrOn Pharmaceuticals
Compare insights from companies similar to NurrOn Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
2011
Mark KlevenSenior Vice President, Scientific Operations, Chief Operating Officer
Company Profile Activity
Activity Insights
NurrOn Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NurrOn Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NurrOn Pharmaceuticals.
NurrOn Pharmaceuticals Tech Stack
A closer look at the technologies used by NurrOn Pharmaceuticals
NurrOn Pharmaceuticals News & Media
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum
ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place on January 7th, 2024, at the historic Marines' Memorial Club in San Francisco, California. The forum immediately precedes the JP Morgan Healthcare Conference, beginning January 8th. The collaborative efforts of HanAllHanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors
WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to announce the appointment of Dr. Almira Chabi, MD, EGMP to its Board of Directors, effective November 24, 2023. Dr. Chabi who is currently Chief Medical Officer and Chief Development Officer at HanAll PhHanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192
HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson's Disease in collaboration with NurrOn Pharmaceuticals. The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of both single and multiple doses of orally administered HL192 in healthy participants. The companies have also entered a strategic partnership with NurrOn Pharmaceuticals to explore the potential of HL192 in an arHanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease
HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders Phase 1 clinical trial is...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NurrOn Pharmaceuticals
Sign Up For FreeTo access detailed company insights
NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, USA, focused on developing innovative, disease-modifying therapies for Parkinson's disease and other Nurr1-related disorders. The company aims to enhance the quality of life for Parkinson's patients by creating targeted therapeutics that maximize efficacy while mi... Read More
